Molecular classification of hepatocellular carcinoma: potential therapeutic implications

References

• El-Serag HB , KanwalF. Epidemiology of hepatocellular carcinoma in the United States: where are we? where do we go?Hepatology60(5), 1767–1775 (2014).
   PubMed Web of Science ®Google Scholar
• Siegel R , MaJ, ZouZ, JemalA. Cancer statistics, 2014. CA Cancer J. Clin.64(1), 9–29 (2014).
   PubMed Web of Science ®Google Scholar
• Forner A , LlovetJM, BruixJ. Hepatocellular carcinoma. Lancet379(9822), 1245–1255 (2012).
   PubMed Web of Science ®Google Scholar
• Llovet JM , Hernandez-GeaV. Hepatocellular carcinoma: reasons for Phase III failure and novel perspectives on trial design. Clin. Cancer Res.20(8), 2072–2079 (2014).
   PubMed Web of Science ®Google Scholar
• Noureddin M , RinellaME. Nonalcoholic fatty liver disease, diabetes, obesity, and hepatocellular carcinoma. Clin. Liver Dis.19(2), 361–379 (2015).
   PubMed Web of Science ®Google Scholar
• Kawada N , ImanakaK, KawaguchiTet al. Hepatocellular carcinoma arising from non-cirrhotic nonalcoholic steatohepatitis. J. Gastroenterol.44(12), 1190–1194 (2009).
   PubMed Web of Science ®Google Scholar
• Wong RJ , CheungR, AhmedA. Nonalcoholic steatohepatitis is the most rapidly growing indication for liver transplantation in patients with hepatocellular carcinoma in the US. Hepatology59(6), 2188–2195 (2014).
   PubMed Web of Science ®Google Scholar
• Viganò L , ConciS, CesconMet al. Liver resection for hepatocellular carcinoma in patients with metabolic syndrome: a multicenter matched analysis with HCV-related HCC. J. Hepatol.63(1), 93–101 (2015).
   PubMed Web of Science ®Google Scholar
• Weinmann A , AltY, KochSet al. Treatment and survival of non-alcoholic steatohepatitis associated hepatocellular carcinoma. BMC Cancer15(1), 210 (2015).
   PubMed Web of Science ®Google Scholar
• Feeney ER , ChungRT. Antiviral treatment of hepatitis C. BMJ348, g3308 (2014).
   PubMedGoogle Scholar
• Thomas DL . Global control of hepatitis C: where challenge meets opportunity. Nat. Med.19(7), 850–858 (2013).
   PubMed Web of Science ®Google Scholar
• Chung RT , BaumertTF. Curing chronic hepatitis C – the arc of a medical triumph. N. Engl. J. Med.370(17), 1576–1578 (2014).
   PubMed Web of Science ®Google Scholar
• Morgan RL , BaackB, SmithBD, YartelA, PitasiM, Falck-YtterY. Eradication of hepatitis c virus infection and the development of hepatocellular carcinoma: a meta-analysis of observational studies. Ann. Intern. Med.158(5 Pt 1), 329–337 (2013).
   PubMed Web of Science ®Google Scholar
• Aleman S , RahbinN, WeilandOet al. A risk for hepatocellular carcinoma persists long-term after sustained virologic response in patients with hepatitis C-associated liver cirrhosis. Clin. Infect. Dis.57(2), 230–236 (2013).
   PubMed Web of Science ®Google Scholar
• Van Der Meer AJ , VeldtBJ, FeldJJet al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA308(24), 2584–2593 (2012).
   PubMed Web of Science ®Google Scholar
• Harris RJ , ThomasB, GriffithsJet al. Increased uptake and new therapies are needed to avert rising hepatitis c-related end stage liver disease in England: modelling the predicted impact of treatment under different scenarios. J. Hepatol.61(3), 530–537 (2014).
   PubMed Web of Science ®Google Scholar
• Llovet JM , RicciS, MazzaferroVet al. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med.359(4), 378–390 (2008).
   PubMed Web of Science ®Google Scholar
• Cheng AL , KangYK, ChenZet al. Efficacy and safety of sorafenib in patients in the Asia-pacific region with advanced hepatocellular carcinoma: a Phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol.10(1), 25–34 (2009).
   PubMed Web of Science ®Google Scholar
• Scudellari M . Drug development: try and try again. Nature516(7529), S4–S6 (2014).
   PubMed Web of Science ®Google Scholar
• Zhu A , RyooB, YenC, KudoM, PoonR, PastorelliD. Ramucirumab (ram) as second-line treatment in patients (pts) with advanced hepatocellular carcinoma (HCC) following first-line therapy with sorafenib: results from the randomized Phase III reach study. Ann. Oncol.25, v1–v41 (2014).
   Google Scholar
• Zhu AX , RosmorducO, EvansTJet al. Search: a Phase III, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in patients with advanced hepatocellular carcinoma. J. Clin. Oncol. JCO33(6), 559–566 (2015).
   PubMed Web of Science ®Google Scholar
• Cainap C , QinS, HuangW-Tet al. Linifanib versus sorafenib in patients with advanced hepatocellular carcinoma: results of a randomized Phase III trial. J. Clin. Oncol.33(2), 172–179 (2015).
   PubMed Web of Science ®Google Scholar
• Cheng A-L , KangY-K, LinD-Yet al. Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized Phase III trial. J. Clin. Oncol.31(32), 4067–4075 (2013).
   PubMed Web of Science ®Google Scholar
• Johnson PJ , QinS, ParkJ-Wet al. Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized Phase III brisk-fl study. J. Clin. Oncol.31(28), 3517–3524 (2013).
   PubMed Web of Science ®Google Scholar
• Shaw AT , KimDW, NakagawaKet al. Crizotinib versus chemotherapy in advanced alk-positive lung cancer. N. Engl. J. Med.368(25), 2385–2394 (2013).
   PubMed Web of Science ®Google Scholar
• Bruix J , FinnRS, KudoMet al. Resource: an ongoing randomized, double-blind, Phase III trial of regorafenib (reg) in patients with hepatocellular carcinoma (HCC) progressing on sorafenib (SOR). Presented at: ASCO Annual Meeting Proceedings. Chicago, IL, USA, 30 May–3 June 2014.
   Google Scholar
• Finn RS , ChengA-L, IkedaKet al. A multicenter, open-label, Phase 3 trial to compare the efficacy and safety of lenvatinib (e7080) versus sorafenib in first-line treatment of subjects with unresectable hepatocellular carcinoma. Presented at: ASCO Annual Meeting Proceedings. Chicago, IL, USA, 30 May–3 June 2014.
   Google Scholar
• Mcnamara MG , LeLW, HorganAMet al. A Phase II trial of second‐line axitinib following prior antiangiogenic therapy in advanced hepatocellular carcinoma. Cancer121(10), 1620–1627 (2015).
   PubMed Web of Science ®Google Scholar
• Abou-Alfa GK , ChengA-L, MeyerTet al. Phase 3 randomized, double-blind, controlled study of cabozantinib (xl184) versus placebo in subjects with hepatocellular carcinoma who have received prior sorafenib (celestial; nct01908426). Presented at: ASCO Annual Meeting Proceedings. Chicago, IL, USA, 30 May–3 June 2014.
   Google Scholar
• Sangro B , CrocenziTS, WellingTHet al. Phase I dose escalation study of nivolumab (anti-pd-1; bms-936558; ono-4538) in patients (pts) with advanced hepatocellular carcinoma (HCC) with or without chronic viral hepatitis. Presented at: ASCO Annual Meeting Proceedings. Chicago, IL, USA, 31 May–4 June 2013.
   Google Scholar
• Santoro A , RimassaL, BorbathIet al. Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled Phase 2 study. Lancet Oncol.14(1), 55–63 (2013).
   PubMed Web of Science ®Google Scholar
• Rimassa L , PortaC, BorbathIet al. Tivantinib in met-high hepatocellular carcinoma patients and the ongoing Phase III clinical trial. Hepatic Oncol.1(2), 181–188 (2014).
   PubMedGoogle Scholar
• Lim HY , HeoJ, ChoiHJet al. A Phase II study of the efficacy and safety of the combination therapy of the MEK inhibitor refametinib (BAY 86–9766) plus sorafenib for Asian patients with unresectable hepatocellular carcinoma. Clin. Cancer Res.20(23), 5976–5985 (2014).
   PubMed Web of Science ®Google Scholar
• Zhu AX , RyooB-Y, YenC-Jet al. Ramucirumab (RAM) as second-line treatment in patients (pts) with advanced hepatocellular carcinoma (HCC): analysis of patients with elevated {alpha}-fetoprotein (AFP) from the randomized Phase III reach study. Presented at: ASCO Annual Meeting Proceedings. Chicago, IL, USA, 29 May–2 June 2015.
   Google Scholar
• Hoshida Y , NijmanSM, KobayashiMet al. Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma. Cancer Res.69(18), 7385–7392 (2009).
   PubMed Web of Science ®Google Scholar
• Hoshida Y , ToffaninS, LachenmayerA, VillanuevaA, MinguezB, LlovetJM. Molecular classification and novel targets in hepatocellular carcinoma: recent advancements. Semin. Liver Dis.30(1), 35–51 (2010).
   PubMed Web of Science ®Google Scholar
• Kaposi-Novak P , LeeJS, Gomez-QuirozL, CoulouarnC, FactorVM, ThorgeirssonSS. Met-regulated expression signature defines a subset of human hepatocellular carcinomas with poor prognosis and aggressive phenotype. J. Clin. Invest.116(6), 1582–1595 (2006).
   PubMed Web of Science ®Google Scholar
• Andersen JB , LoiR, PerraAet al. Progenitor-derived hepatocellular carcinoma model in the rat. Hepatology51(4), 1401–1409 (2010).
   PubMed Web of Science ®Google Scholar
• Villanueva A , HoshidaY, BattistonCet al. Combining clinical, pathology, and gene expression data to predict recurrence of hepatocellular carcinoma. Gastroenterology140(5), 1501–1512, e1502 (2011).
   PubMed Web of Science ®Google Scholar
• Lee JS , ChuIS, HeoJet al. Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling. Hepatology40(3), 667–676 (2004).
   PubMed Web of Science ®Google Scholar
• Kim SM , LeemSH, ChuISet al. Sixty-five gene-based risk score classifier predicts overall survival in hepatocellular carcinoma. Hepatology55(5), 1443–1452 (2012).
   PubMed Web of Science ®Google Scholar
• Woo HG , ParkES, CheonJHet al. Gene expression-based recurrence prediction of hepatitis B virus-related human hepatocellular carcinoma. Clin. Cancer Res.14(7), 2056–2064 (2008).
   PubMed Web of Science ®Google Scholar
• Wang SM , OoiLL, HuiKM. Identification and validation of a novel gene signature associated with the recurrence of human hepatocellular carcinoma. Clin. Cancer Res.13(21), 6275–6283 (2007).
   PubMed Web of Science ®Google Scholar
• Katoh H , OjimaH, KokubuAet al. Genetically distinct and clinically relevant classification of hepatocellular carcinoma: putative therapeutic targets. Gastroenterology133(5), 1475–1486 (2007).
   PubMed Web of Science ®Google Scholar
• Laurent-Puig P , LegoixP, BluteauOet al. Genetic alterations associated with hepatocellular carcinomas define distinct pathways of hepatocarcinogenesis. Gastroenterology120(7), 1763–1773 (2001).
   PubMed Web of Science ®Google Scholar
• Coulouarn C , FactorVM, ThorgeirssonSS. Transforming growth factor-beta gene expression signature in mouse hepatocytes predicts clinical outcome in human cancer. Hepatology47(6), 2059–2067 (2008).
   PubMed Web of Science ®Google Scholar
• Woo HG , LeeJH, YoonJHet al. Identification of a cholangiocarcinoma-like gene expression trait in hepatocellular carcinoma. Cancer Res.70(8), 3034–3041 (2010).
   PubMed Web of Science ®Google Scholar
• Oishi N , KumarMR, RoesslerSet al. Transcriptomic profiling reveals hepatic stem-like gene signatures and interplay of mir-200c and epithelial–mesenchymal transition in intrahepatic cholangiocarcinoma. Hepatology56(5), 1792–1803 (2012).
   PubMed Web of Science ®Google Scholar
• Lee JS , HeoJ, LibbrechtLet al. A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells. Nat. Med.12(4), 410–416 (2006).
   PubMed Web of Science ®Google Scholar
• Yamashita T , ForguesM, WangWet al. Epcam and alpha-fetoprotein expression defines novel prognostic subtypes of hepatocellular carcinoma. Cancer Res.68(5), 1451–1461 (2008).
   PubMed Web of Science ®Google Scholar
• Breuhahn K , VredenS, HaddadRet al. Molecular profiling of human hepatocellular carcinoma defines mutually exclusive interferon regulation and insulin-like growth factor II overexpression. Cancer Res.64(17), 6058–6064 (2004).
   PubMed Web of Science ®Google Scholar
• Yamashita T , JiJ, BudhuAet al. Epcam-positive hepatocellular carcinoma cells are tumor-initiating cells with stem/progenitor cell features. Gastroenterology136(3), 1012–1024 (2009).
   PubMed Web of Science ®Google Scholar
• Cairo S , ArmengolC, De ReyniesAet al. Hepatic stem-like phenotype and interplay of wnt/beta-catenin and myc signaling in aggressive childhood liver cancer. Cancer Cell14(6), 471–484 (2008).
   PubMed Web of Science ®Google Scholar
• Minguez B , HoshidaY, VillanuevaAet al. Gene-expression signature of vascular invasion in hepatocellular carcinoma. J. Hepatol.55(6), 1325–1331 (2011).
   PubMed Web of Science ®Google Scholar
• Sherman M . Hepatocellular carcinoma: epidemiology, risk factors, and screening. Semin Liver Dis25(2), 143–154 (2005).
   PubMed Web of Science ®Google Scholar
• Zucman-Rossi J , BenhamoucheS, GodardCet al. Differential effects of inactivated axin1 and activated beta-catenin mutations in human hepatocellular carcinomas. Oncogene26(5), 774–780 (2007).
   PubMed Web of Science ®Google Scholar
• Boyault S , RickmanDS, De ReyniesAet al. Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets. Hepatology45(1), 42–52 (2007).
   PubMed Web of Science ®Google Scholar
• Chiang DY , VillanuevaA, HoshidaYet al. Focal gains of vegfa and molecular classification of hepatocellular carcinoma. Cancer Res.68(16), 6779–6788 (2008).
   PubMed Web of Science ®Google Scholar
• White BD , ChienAJ, DawsonDW. Dysregulation of wnt/beta-catenin signaling in gastrointestinal cancers. Gastroenterology142(2), 219–232 (2012).
   PubMed Web of Science ®Google Scholar
• Schulze K , ImbeaudS, LetouzeEet al. Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets. Nat. Genet.47(5), 505–511 (2015).
   PubMed Web of Science ®Google Scholar
• Totoki Y , TatsunoK, CovingtonKRet al. Trans-ancestry mutational landscape of hepatocellular carcinoma genomes. Nat. Genet.46(12), 1267–1273 (2014).
   PubMed Web of Science ®Google Scholar
• Okabe H , SatohS, KatoTet al. Genome-wide analysis of gene expression in human hepatocellular carcinomas using cDNA microarray: identification of genes involved in viral carcinogenesis and tumor progression. Cancer Res.61(5), 2129–2137 (2001).
   PubMed Web of Science ®Google Scholar
• Iizuka N , OkaM, Yamada-OkabeHet al. Comparison of gene expression profiles between hepatitis B virus- and hepatitis C virus-infected hepatocellular carcinoma by oligonucleotide microarray data on the basis of a supervised learning method. Cancer Res.62(14), 3939–3944 (2002).
   PubMed Web of Science ®Google Scholar
• Honda M , YamashitaT, UedaT, TakatoriH, NishinoR, KanekoS. Different signaling pathways in the livers of patients with chronic hepatitis B or chronic hepatitis C. Hepatology44(5), 1122–1138 (2006).
   PubMed Web of Science ®Google Scholar
• Sung WK , ZhengH, LiSet al. Genome-wide survey of recurrent HBV integration in hepatocellular carcinoma. Nat. Genet.44(7), 765–769 (2012).
   PubMed Web of Science ®Google Scholar
• Tan PS , NakagawaS, GoossensNet al. Clinicopathological indices to predict hepatocellular carcinoma molecular classification. Liver Int. doi:10.1111/liv.12889 (2015) ( Epub ahead of print).
   Web of Science ®Google Scholar
• Salomao M , YuWM, BrownRSJr, EmondJC, LefkowitchJH. Steatohepatitic hepatocellular carcinoma (SH-HCC): a distinctive histological variant of HCC in hepatitis C virus-related cirrhosis with associated NAFLD/NASH. Am. J. Surg. Pathol.34(11), 1630–1636 (2010).
   PubMed Web of Science ®Google Scholar
• Lee JS , ChuIS, MikaelyanAet al. Application of comparative functional genomics to identify best-fit mouse models to study human cancer. Nat. Genet.36(12), 1306–1311 (2004).
   PubMed Web of Science ®Google Scholar
• Lee JS , ThorgeirssonSS. Functional and genomic implications of global gene expression profiles in cell lines from human hepatocellular cancer. Hepatology35(5), 1134–1143 (2002).
   PubMed Web of Science ®Google Scholar
• Kawai HF , KanekoS, HondaM, ShirotaY, KobayashiK. Alpha-fetoprotein-producing hepatoma cell lines share common expression profiles of genes in various categories demonstrated by cDNA microarray analysis. Hepatology33(3), 676–691 (2001).
   PubMed Web of Science ®Google Scholar
• Finn RS , AleshinA, DeringJet al. Molecular subtype and response to dasatinib, an Src/Abl small molecule kinase inhibitor, in hepatocellular carcinoma cell lines in vitro. Hepatology57(5), 1838–1846 (2013).
   PubMed Web of Science ®Google Scholar
• Deshmukh M , HoshidaY. Genomic profiling of cell lines for personalized targeted therapy for hepatocellular carcinoma. Hepatology58(6), 2207 (2013).
   PubMed Web of Science ®Google Scholar
• Hoshida Y , VillanuevaA, KobayashiMet al. Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N. Engl. J. Med.359(19), 1995–2004 (2008).
   PubMed Web of Science ®Google Scholar
• Imamura H , MatsuyamaY, TanakaEet al. Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. J. Hepatol.38(2), 200–207 (2003).
   PubMed Web of Science ®Google Scholar
• Lai CL , WuPC, LamKC, ToddD. Histologic prognostic indicators in hepatocellular carcinoma. Cancer44(5), 1677–1683 (1979).
   PubMed Web of Science ®Google Scholar
• Audisio RA , BombelliL, LombardiL, AndreolaS. A clinico-pathologic study of clear-cell hepatocellular carcinoma. Tumori73(4), 389–395 (1987).
   PubMedGoogle Scholar
• Kim JH , SohnBH, LeeHSet al. Genomic predictors for recurrence patterns of hepatocellular carcinoma: model derivation and validation. PLoS Med.11(12), e1001770 (2014).
   PubMed Web of Science ®Google Scholar
• Hong Y , PengY, GuoZSet al. Epitope-optimized alpha-fetoprotein genetic vaccines prevent carcinogen-induced murine autochthonous hepatocellular carcinoma. Hepatology59(4), 1448–1458 (2014).
   PubMed Web of Science ®Google Scholar
• Zhu AX , GoldPJ, El-KhoueiryABet al. First-in-man Phase I study of gc33, a novel recombinant humanized antibody against glypican-3, in patients with advanced hepatocellular carcinoma. Clin. Cancer Res.19(4), 920–928 (2013).
   PubMed Web of Science ®Google Scholar
• Ikeda M , OhkawaS, OkusakaTet al. Japanese Phase I study of gc33, a humanized antibody against glypican-3 for advanced hepatocellular carcinoma. Cancer Sci.105(4), 455–462 (2014).
   PubMed Web of Science ®Google Scholar
• Giannelli G , VillaE, LahnM. Transforming growth factor-beta as a therapeutic target in hepatocellular carcinoma. Cancer Res.74(7), 1890–1894 (2014).
   PubMed Web of Science ®Google Scholar
• Michieli P , Di NicolantonioF. Targeted therapies: Tivantinib – a cytotoxic drug in met inhibitor’s clothes?Nat. Rev. Clin. Oncol.10(7), 372–374 (2013).
   PubMed Web of Science ®Google Scholar
• Collins FS , VarmusH. A new initiative on precision medicine. N. Engl. J. Med.372(9), 793–795 (2015).
   PubMed Web of Science ®Google Scholar
• Chen X , CheungST, SoSet al. Gene expression patterns in human liver cancers. Mol. Biol. Cell.13(6), 1929–1939 (2002).
   PubMed Web of Science ®Google Scholar
• Ye QH , QinLX, ForguesMet al. Predicting hepatitis b virus-positive metastatic hepatocellular carcinomas using gene expression profiling and supervised machine learning. Nat. Med.9(4), 416–423 (2003).
   PubMed Web of Science ®Google Scholar
• Llovet JM , ChenY, WurmbachEet al. A molecular signature to discriminate dysplastic nodules from early hepatocellular carcinoma in HCV cirrhosis. Gastroenterology131(6), 1758–1767 (2006).
   PubMed Web of Science ®Google Scholar
• Villa E , CritelliR, LeiBet al. Neoangiogenesis-related genes are hallmarks of fast-growing hepatocellular carcinomas and worst survival. Results from a prospective study. Gut doi:10.1136/gutjnl-2014-308483 (2015) ( Epub ahead of print).
   PubMed Web of Science ®Google Scholar
• Iizuka N , OkaM, Yamada-OkabeHet al. Oligonucleotide microarray for prediction of early intrahepatic recurrence of hepatocellular carcinoma after curative resection. Lancet361(9361), 923–929 (2003).
   PubMed Web of Science ®Google Scholar
• Roessler S , JiaHL, BudhuAet al. A unique metastasis gene signature enables prediction of tumor relapse in early-stage hepatocellular carcinoma patients. Cancer Res.70(24), 10202–10212 (2010).
   PubMed Web of Science ®Google Scholar
• Kurokawa Y , MatobaR, TakemasaIet al. Molecular-based prediction of early recurrence in hepatocellular carcinoma. J. Hepatol.41(2), 284–291 (2004).
   PubMed Web of Science ®Google Scholar
• Yoshioka S , TakemasaI, NaganoHet al. Molecular prediction of early recurrence after resection of hepatocellular carcinoma. Eur. J. Cancer45(5), 881–889 (2009).
   PubMed Web of Science ®Google Scholar
• Nault JC , De ReyniesA, VillanuevaAet al. A hepatocellular carcinoma 5-gene score associated with survival of patients after liver resection. Gastroenterology145(1), 176–187 (2013).
   PubMed Web of Science ®Google Scholar